Guillain-Barré syndrome following the first dose of SARS-CoV-2 vaccine: A temporal occurrence, not a causal association
Osakpolor Ogbebor, Harshit Seth, Zaw Min, Nitin Bhanot
Abstract
Safety monitoring is of paramount importance for vaccines authorized for emergent use (EUA) by the US Food and Drug Administration (FDA) against SARS-CoV-2. Mass immunization is an essential tool to end the current pandemic, but vaccine surveillance is necessary to identify any potentially associated harms. At the same time, probability of temporal bias should be borne in mind before making conclusions about causality between the vaccine and an attributable undesired effect. We report a case of Guillain-Barré syndrome after the first dose of SARS-CoV-2 vaccine and believe this is a temporal, rather than causal association.
Topics & Concepts
MedicinePandemicFood and drug administrationCausality (physics)ImmunizationCoronavirus disease 2019 (COVID-19)Guillain-Barre syndromeSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Vaccine safety2019-20 coronavirus outbreakVaccinationIntensive care medicineVirologyImmunologyEnvironmental healthOutbreakDiseaseInfectious disease (medical specialty)PathologyAntibodyQuantum mechanicsPhysicsPeripheral Neuropathies and DisordersSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19